Integra LifeSciences
Integra LifeSciences (NASDAQ: IART) is a global medical device company that develops and sells surgical implants, regenerative collagen products, ultrasonic tissue ablation systems, and AI-assisted ENT navigation tools to hospital systems, ambulatory surgery centers, and physician practices across neurosurgery, wound reconstruction, ENT, and surgical instrumentation.
- Company typePublic
- Founded1989
- HeadquartersPrinceton, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Integra LifeSciences does
Integra LifeSciences Holdings Corporation (NASDAQ: IART) is a Princeton, New Jersey-based global medical technology company founded in 1989 that develops, manufactures, and sells medical devices and regenerative tissue products for neurosurgery, wound reconstruction, ENT, plastic and reconstructive surgery, and general surgical instrumentation. Its product architecture rests on six integrated platforms: (1) Neurosurgery and tissue ablation (CUSA Clarity ultrasonic aspirator, dural repair, cranial reconstruction and stabilization, Aurora minimally invasive surgery); (2) Neurocritical care and hydrocephalus management (external CSF drainage, fixed/flow-regulating/programmable valves, catheters); (3) Wound reconstruction (Integra Dermal Matrices, PriMatrix Dermal Scaffold, MicroMatrix UBM and Cytal, AmnioExcel, MediHoney); (4) Soft tissue solutions (nerve and tendon, hernia repair, plastic and reconstructive); (5) Surgical instrumentation and lighting under brands such as Jarit, MicroFrance, Miltex, Padgett, Omni-Tract, Ruggles-Redmond, and Integra DUO/MLX/Luxtec lighting; and (6) ENT (TruDi AI-powered navigation, balloon sinuplasty, airway/nasal/eustachian dilation) acquired via the $275M Acclarent purchase in April 2024.
Underlying technology is anchored in proprietary collagen biomaterials (Ultra Pure Collagen from bovine deep flexor tendon) with demonstrated safety in over 10 million implants, plus tissue ablation, programmable valve, and AI-assisted surgical navigation platforms. The company generates revenue primarily through direct sales of capital equipment and consumables to hospital systems, ambulatory surgery centers, and physician practices via a global field sales organization led by a Chief Commercial Officer, with manufacturing across 24 plants in the U.S., Puerto Rico, Mexico, Europe, and China.
In FY2025, Integra reported $1,635.2 million in revenue (up 1.5% reported, down 0.7% organically), with Q1 2026 revenue of $392 million (+2.4% reported) and FY2026 guidance of $1,662–$1,702 million. The company employs 4,200+ people globally and is led by Stuart M. Essig, who returned as President and CEO in May 2026 after previously serving as CEO from 1997 to 2012. Material recent developments include the Acclarent acquisition (ENT platform), a new CCO and CTO, FDA 510(k) clearance for CUSA Clarity in cardiac surgery, ongoing TruDi navigation AI safety concerns and litigation, and a MediHoney wound and burn product recall that triggered 65 Princeton job cuts.
Integra LifeSciences firmographics
Firmographics- Name
- Integra LifeSciences
- Legal name
- Integra LifeSciences Holdings Corporation
- Website
- https://integralife.com
- Company type
- Public
- Founded year
- 1989
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Integra LifeSciences (NASDAQ: IART) is a global medical device company that develops and sells surgical implants, regenerative collagen products, ultrasonic tissue ablation systems, and AI-assisted ENT navigation tools to hospital systems, ambulatory surgery centers, and physician practices across neurosurgery, wound reconstruction, ENT, and surgical instrumentation.
- Ownership category
- akta.pro rank
Integra LifeSciences industry classification
Industry- Product category
- Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)
- akta.pro secondary industries
- Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT) (HLAHADAG), Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits) (HLAHADAM), Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)
Keywords
Where Integra LifeSciences is headquartered
LocationHeadquarters
- HQ city
- Princeton
- HQ country
- United States
- HQ region
- North America
Offices11 records
Markets served
Integra LifeSciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Medical Device and Product Sales: Sales of surgical instruments, implants, wound care products, and capital equipment to hospitals and healthcare providers. Revenue includes both one-time product sales and recurring consumables.
- Product Portfolio Revenue: Full-year 2025 revenues of $1,635.2 million, with Q4 2025 revenues of $434.9 million and Q1 2026 revenues of $392 million
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Medical device products sold to healthcare providers |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Integra LifeSciences product offering
Product offeringCore offering
Integra LifeSciences designs, manufactures, and sells medical devices and regenerative tissue technologies used in neurosurgery, wound reconstruction, ENT surgery, and general surgical procedures. Its portfolio spans capital equipment (e.g., CUSA tissue ablation systems), implants and consumables (dural repair, hydrocephalus valves, cranial stabilization), engineered collagen and amniotic wound matrices, surgical instruments, surgical lighting, and ENT balloon and navigation systems, sold to hospitals, ambulatory surgery centers, and physician practices worldwide.
Product overview
Integra LifeSciences is a global medical technology company offering a diversified portfolio of highly differentiated products and solutions across neurosurgery and tissue reconstruction. The company's product architecture consists of multiple integrated platforms: (1) Neurosurgery/Tissue Ablation (CUSA Clarity, Dural Repair, Cranial Reconstruction, Cranial Stabilization, Minimally Invasive Surgery with Aurora Surgiscope), (2) Neurocritical Care/Hydrocephalus Management (External CSF Drainage, Fixed/Programmable/Flow Regulating Valves, Catheters), (3) Wound Reconstruction and Care (Integra Dermal Matrices, PriMatrix Dermal Scaffold, MicroMatrix UBM/Cytal Wound Matrix, AmnioExcel Allografts, MediHoney Dressings, Total Contact Casting), (4) Soft Tissue Solutions (Nerve & Tendon, Hernia Repair, Plastic Reconstructive Surgery), (5) Surgical Instrumentation and Lighting (Surgical Instruments under multiple brands including Jarit, MicroFrance, Miltex; Surgical Lighting including Integra DUO LED, Luxtec), and (6) Ear, Nose and Throat (ENT) portfolio acquired through Acclarent including TruDi Navigation System with AI capabilities, Balloon Sinuplasty, Airway/Nasal Dilation Systems, and Eustachian Tube Balloon Dilation. The company operates across 24 global manufacturing plants and serves healthcare professionals in multiple surgical specialties.
Differentiator
Problem solved
Functional benefit
Brands
- Codman Specialty Surgical: Neurosurgery and neuro-critical care products including dural repair, CSF management, cranial stabilization and fixation
- Acclarent
- Tissue Technologies
- CUSA
- Aurora
- Integra ENT
- Jarit
- MicroFrance
- Miltex
Products and services
- CUSA Clarity Ultrasonic Surgical Aspirator System Capital equipment system for ultrasonic surgical tissue ablation in neurosurgery, orthopedic, liver, and cardiac procedures, including the CUSA Clarity model cleared for cardiac use in November 2025.
- Dural Repair Products Dural substitutes and repair materials used by neurosurgeons to close the dura mater following cranial and spinal procedures.
- Cranial Reconstruction Implants
- Cranial Stabilization and Fixation Devices
- Aurora Minimally Invasive Surgery System
- Neuro ICU / External CSF Drainage Products
- Hydrocephalus Management Products
- Integra Dermal Matrices
- PriMatrix Dermal Scaffold Fetal bovine dermis dermal scaffold for wound reconstruction in partial and full-thickness wounds, pressure ulcers, diabetic ulcers, venous ulcers, and surgical wounds.
- MicroMatrix UBM and Cytal Wound Matrix Urinary bladder matrix (UBM) particulate and sheet products, including MicroMatrix Flex and Cytal Wound Matrix, for complex wound management.
- AmnioExcel Amniotic and Placental Allograft Membranes
- MediHoney Wound and Burn Dressing
- Nerve and Tendon Repair Products
- Hernia Repair and Abdominal Wall Products
- Plastic and Reconstructive Surgery Products
- Surgical Instruments (Integra, Jarit, MicroFrance, Omni-Tract, Ruggles-Redmond, Padgett, Miltex)
- Surgical Lighting Systems
- TruDi Navigation System
- Balloon Sinuplasty Products
- Airway Dilation System
- Nasal Dilation System
- Eustachian Tube Balloon Dilation System
Quantifiable outcome
- Fetal bovine dermis-based PriMatrix supported vascularized tissue formation prior to definitive closure, accelerating patient recovery timeline
- +1 more outcomes
Companies that use Integra LifeSciences
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles3 records
Integra LifeSciences technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Integra LifeSciences partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered supporting, core and minor.
- Morgan LewissupportingMorgan Lewis law firm represented Integra LifeSciences in the acquisition of Acclarent from Johnson & Johnson
- Ethicon, Inc. (Johnson & Johnson)coreAcclarent, Inc. was acquired from Ethicon, Inc., expanding Integra's presence in the ENT device segment with innovative balloon technologies and surgical systems
- Companies Seeking Collagen PartnershipsminorIntegra offers collagen biomaterial expertise for companies seeking strategic alliances including private label partnerships, material supply, and customer-specific product development
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
Integra LifeSciences competitors and assessment
Company assessmentDirect peers
- Medtronic: Medtronic is the global leader in neurosurgery, ENT (via Mazor and cranial therapies), and surgical instruments with significantly broader scale. Directly comparable to Integra's Codman, CUSA, TruDi, and Acclarent franchises and competes for the same neurosurgery and ENT hospital budgets.
- Stryker: Stryker operates a large surgical instruments, neurosurgery, and ENT business (acquired Wright Medical, Entellus) competing directly against Integra's surgical instrument, cranial fixation, and balloon sinuplasty portfolios. Comparable in serving the same surgical suite customers with hospital-wide contracts.
- Conmed: Conmed is a mid-cap surgical and ENT device company with a comparable product mix spanning ENT surgical instruments, electrosurgery, and general surgical devices. Closest peer by size, business model, and ENT focus, competing with both Integra's Acclarent franchise and Jarit/MicroFrance surgical instruments.
- Smith+Nephew: Smith+Nephew operates a significant advanced wound management business (Allevyn, PICO) competing directly with Integra's PriMatrix, MicroMatrix, and MediHoney portfolios. Also a direct competitor in surgical instruments and ENT, making it one of the most product-overlapping peers.
Broad incumbents
- Johnson & Johnson MedTech: J&J MedTech (Ethicon, DePuy Synthes) sold Codman Neurosurgery to Integra in 2017 and Acclarent to Integra in 2024, and remains a broad incumbent with overlapping ENT, surgical instruments, wound closure, and neurosurgery offerings. Highly comparable for competitive context even though Integra has divested product lines back to J&J over time.
- Baxter International: Baxter's Medical Products and Therapies segment overlaps with Integra's surgical and wound reconstruction businesses, particularly in hydrocephalus shunts (Baxter historically strong), dura repair, and advanced wound care. Comparable broad medtech peer with similar hospital channel.
- Becton Dickinson (BD): BD's BDX Medical segment produces surgical instruments, infection prevention, and biosurgery products overlapping with Integra's Miltex surgical instruments, Jarit, MicroFrance, and dural/sealant portfolio. Comparable as a hospital-channel surgical device incumbent.
Emerging players
- Organogenesis: Organogenesis is a smaller pure-play in advanced wound care and regenerative medicine (Apligraf, Dermagraft), competing head-to-head with Integra's PriMatrix, AmnioExcel, and Cytal wound matrices. Directly comparable technology platform and call point in wound care specialists.
- MiMedx: MiMedx is a smaller regenerative medicine company focused on amniotic membrane allografts (EpiFix, AmnioFix) and wound care, directly competing with Integra's AmnioExcel portfolio. Comparable technology and call point though significantly smaller scale.
- Coloplast: Coloplast's Wound & Skin Care division (Biatain, Conveen) competes with Integra's advanced wound care and skin substitute products, particularly in chronic wound management. Comparable wound care call point though Coloplast is stronger in ostomy and continence care.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Integra LifeSciences social profiles
Digital presenceIntegra LifeSciences compliance and trust
Trust signalCompliance2 records
Integra LifeSciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Integra LifeSciences leadership team
Management profileNumber of profiles
Profiles9 records
Integra LifeSciences subsidiaries and ownership
Company hierarchySubsidiaries3 records
Integra LifeSciences funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Integra LifeSciences M&A and investment
M&A and investmentM&A22 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Integra LifeSciences
What does Integra LifeSciences do?
Integra LifeSciences designs, manufactures, and sells medical devices and regenerative tissue technologies used in neurosurgery, wound reconstruction, ENT surgery, and general surgical procedures. Its portfolio spans capital equipment (e.g., CUSA tissue ablation systems), implants and consumables (dural repair, hydrocephalus valves, cranial stabilization), engineered collagen and amniotic wound matrices, surgical instruments, surgical lighting, and ENT balloon and navigation systems, sold to hospitals, ambulatory surgery centers, and physician practices worldwide.
Is Integra LifeSciences a public or private company?
Integra LifeSciences is a public company. It is classified as public and is currently operating.
When was Integra LifeSciences founded?
Integra LifeSciences was founded in 1989. It employs 1,001 to 5,000 people.
Where is Integra LifeSciences based?
Integra LifeSciences is headquartered in Princeton, United States, in the North America region.
How does Integra LifeSciences make money?
Two revenue lines are on record. Medical Device and Product Sales are the primary driver. The others are product Portfolio Revenue.
Who are Integra LifeSciences's main competitors?
Direct peers on record are Medtronic, Stryker, Conmed and Smith+Nephew. Broad incumbents are Johnson & Johnson MedTech, Baxter International and Becton Dickinson (BD). Emerging players are Organogenesis, MiMedx and Coloplast.
Does Integra LifeSciences have an API?
No public API is recorded for Integra LifeSciences.
What industry is Integra LifeSciences in?
Integra LifeSciences's product category is Medical Devices. Its primary akta.pro industry code is HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS), with a secondary code of HLAHADAG, Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT). Its NAICS code is 339112 and its SIC code is 3841.